Payment overview · 2025
General Payments
$150.00
1 reported records · 1 companies
Healthcare provider profile · identity verified
Eli Wercberger, DO
Allopathic & Osteopathic Physicians|Internal Medicine · BAYONNE, NJ · NPI 1023679974
Verified facts
What the public records show
CMS Open Payments records show Eli Wercberger, DO received $150.00 in general payments during 2025 across 1 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $150.00 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 722 | 149 |
| Gabapentin | Gabapentin | 465 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 431 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 294 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 270 | 51 |
| Losartan Potassium | Losartan Potassium | 260 | 52 |
| Metformin Hcl | Metformin Hcl | 241 | 56 |
| Famotidine | Famotidine | 238 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 236 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 45 |
| Eliquis | Apixaban | 204 | 46 |
| Furosemide | Furosemide | 192 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 189 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 179 | 30 |
| Lisinopril | Lisinopril | 155 | 26 |
| Omeprazole | Omeprazole | 147 | 42 |
| Finasteride | Finasteride | 137 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 125 | 24 |
| Levetiracetam | Levetiracetam | 104 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 25 |
| Carvedilol | Carvedilol | 97 | 23 |
| Xarelto | Rivaroxaban | 94 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 89 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 77 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 20 |
| Spironolactone | Spironolactone | 68 | 15 |
| Tramadol Hcl | Tramadol Hcl | 68 | 11 |
| Januvia | Sitagliptin Phosphate | 65 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 64 | 16 |
| Donepezil Hcl | Donepezil Hcl | 63 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 61 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 18 |
| Potassium Chloride | Potassium Chloride | 61 | 17 |
| Nifedipine Er | Nifedipine | 60 | 20 |
| Prednisone | Prednisone | 56 | 20 |
| Mirtazapine | Mirtazapine | 55 | 16 |
| Jardiance | Empagliflozin | 52 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 50 | 11 |
| Entresto | Sacubitril/Valsartan | 50 | 12 |
| Ozempic | Semaglutide | 50 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 49 | 13 |
| Enulose | Lactulose | 47 | suppressed |
| Gemfibrozil | Gemfibrozil | 47 | suppressed |
| Trulicity | Dulaglutide | 47 | 13 |
| Allopurinol | Allopurinol | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | suppressed |
| Simvastatin | Simvastatin | 45 | 11 |
| Glimepiride | Glimepiride | 44 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | suppressed |
| Glipizide | Glipizide | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Celecoxib | Celecoxib | 40 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | suppressed |
| Azithromycin | Azithromycin | 38 | 22 |
| Farxiga | Dapagliflozin Propanediol | 38 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 36 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 36 | suppressed |
| Meloxicam | Meloxicam | 35 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Mesalamine | Mesalamine | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Gemtesa | Vibegron | 31 | suppressed |
| Cilostazol | Cilostazol | 28 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Latanoprost | Latanoprost | 25 | 12 |
| Cinacalcet Hcl | Cinacalcet Hcl | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 24 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Roflumilast | Roflumilast | 22 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 22 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Ethacrynic Acid | Ethacrynic Acid | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $150.00 · 1 records | Otsuka America Pharmaceutical, Inc. | REXULTI | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error